Home > Market Research > Prescription Medicines > The Pharmaceutical Market: Mexico

Table of Contents

Management Report
Published: January 2010
Pages: 87
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00   Buy Now!
Research from: Espicom
Sector: Prescription Medicines

Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

MEXICO - MARKET REVIEW

The exchange rate of the Mexican peso against the US dollar is causing uncertainty, with increasing pharmaceutical import costs. Growth in the private pharmacy sector is expected to be moderate in the next few years. Pfizer’s acquisition of Wyeth and the merger of Merck Sharp & Dohme with Schering Plough will change the sector, with sanofi-aventis being pushed down. In spite of moderate growth, the sector will continue to offer long-term opportunities. Takeda is one of the latest multinational producers to establish a subsidiary in Mexico.

On a positive note, the downturn is fuelling generics consumption. This market, which relies on public sales rather than private pharmacy sales, is expected to double in size in 2010. As a result, a number of foreign producers are strengthening their operations in the country, mainly via acquisitions. Valeant, for instance, acquired a local producer in July 2009. Previously, sanofi-aventis acquired another local producer in the first half of 2009. Local competition is also increasing. Genomma Lab, for instance, launched its generic product portfolio in August 2009, directly competing with members of ANAFAM.

In September 2009, the reform of the LGS that will allow the sale and production of biologic and ‘biocomparable’ medicines in Mexico was enforced; the reform was published in June 2009. Article 222 Bis defines and regulates biologic and biosimilar medicines, including the requirements to register and market these medicines. The new regulation represents sizeable opportunities for both local and foreign producers. Local producers such as Probiomed, Silanes and Landsteiner Scientific already produce biologic medicines in Mexico. Competition, however, is expected to arise from foreign producers. On a patient level, the new regulation provides product safety and availability.

Local manufacturing plant requirements are being phased out over a two-year period. Competition from foreign producers is going to increase, particularly from those which until now did not have the resources to establish manufacturing facilities in Mexico. Imports of antiretrovirals were released in August 2008. Imports of vitamins, homeopathic medicines, vaccines, sera, haemoderivatives, antitoxins and biologic hormones were released in February 2009. Producers of other biologics such as insulin and erythropoietin have been able to export to Mexico since August 2009. The liberation for narcotic or psychotropic drugs and OTC drugs will happen in February 2010. Finally, the market will be fully open by mid 2010.

The reform of the Health Supplies Regulation, published in the Official Bulletin in January 2008, has ‘improved’ the renewal and registration processes of pharmaceuticals, and there will only be patented and bioequivalent generic drugs in the market from 24th February 2010. Of the 10,500 pharmaceuticals whose registrations need to be renewed, the Federal National Commission for Protection against Health Risks (COFEPRIS) estimates that about 17% will exit the market. Many local producers believe that this is a frontal attack against the local pharmaceutical industry. By mid 2009, COFEPRIS indicated that nearly three quarters of the registrations were in process; it believes completion will be on time.

Top of Page

Table of Contents

EXECUTIVE SUMMARY. 1
Snapshot: Strategic Espicom Analysis2
Snapshot: Key Data Projections .3
MACROENVIRONMENT . 4
POLITICAL4
ECONOMIC5
Projections.5
LEGAL.6
Patent Extensions6
DEMOGRAPHIC7
Projections.7
Demographic Indicators.9
Births 9
Deaths 9
Infant Deaths. 9
Life Expectancy at Birth 9
EPIDEMIOLOGY 11
DISEASE BURDEN.11
Leading Causes of Mortality.11
DISEASE PREVALENCE.12
Communicable Diseases.12
HIV/AIDS. 13
Influenza A (H1N1) 14
Non-Communicable Diseases14
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 15
ORGANISATION15
Stewardship.15
Financial Imbalances.15
SOCIAL SECURITY.16
EXPENDITURE.17
Projections.17
Latest Figures.18
SS Health Expenditure18
INFRASTRUCTURE19
Hospital Infrastructure.19
Private Hospital Operators.20
Public Hospital Investments22
Ambulatory Infrastructure.23
SERVICES.24
Hospital Inpatient Services24
Outpatient Services.25
WORKFORCE.26
Projections.26
Segmentation of Physicians.27
Segmentation of Nurses.27
Espicom Business iv Intelligence Q1 2010
Mexico WPM
REGULATORY AFFAIRS.28
NATIONAL AUTHORITY 28
REGULATORY DEVELOPMENTS 28
Regulatory Development for Medical Samples .28
Regulatory Developments for Manufacturing 29
MARKETING REGISTRATION 30
Registration Renewals .31
IMPORT REGULATIONS 32
PROMOTION.32
Advertising 32
PRICING & REIMBURSEMENT 33
PRICING .33
Tax Proposal.33
Pricing in the Private Pharmacy Sector.33
Pricing in the Public Sector.33
REIMBURSEMENT . 34
Reimbursement in the Private Sector.34
Reimbursement in the Public Sector.34
DISTRIBUTION CHANNELS 35
DRUG WHOLESALING35
Association of Wholesalers35
DIPROFAR.35
Leading Wholesalers.36
Grupo Casa Saba 36
Grupo Marzam36
NADRO37
DRUG RETAILING37
Associations of Independent Pharmacies.37
ANAFARMEX37
UPROFARM37
Association of Pharmacy Chains38
ANADIM38
Leading Pharmacy Chains38
Ahorro38
Benavides 38
El Fenix.39
Fasi 39
Fragua.39
Similares.40
MARKET ANALYSIS. 41
SIZE.41
Projections.41
Current Size42
Current Structure.43
Private Pharmacy Sector.43
Public Sector.44
PRODUCT DEVELOPMENT. 45
Private R&D45
Investments.45
Clinical Trials45
MANUFACTURING. 46
Espicom Business Q1 2010 Intelligence
WPM Mexico
TRADE47
Exports.47
Imports.50
Balance of Trade55
COMPETITION.56
TRADE ASSOCIATIONS. 56
AMELAF56
AMIIF.56
ANAPIF56
CANIFARMA 56
TRADE FAIRS 58
EXPOFARMA INTERPHEX 200958
ExpoSALUD y Bienestar58
COMPANY INTELLIGENCE 58
Foreign Private Producers58
Armstrong .58
AstraZeneca58
Bayer.59
Boehringer Ingelheim Promeco59
Bristol-Myers Squibb.59
Eli Lilly.60
GlaxoSmithKline.60
Merck60
Merck Sharp & Dohme 61
Novartis 61
Pfizer.62
Roche62
sanofi-aventis.63
Schering-Plough64
Solvay Pharmaceuticals64
Wyeth.64
Local Private Producers64
Chinoin.64
IFA Celtics.65
Liomont .65
Neolpharma65
Senosiain65
Sophia.66
TechSphere66
COMPETITIVE STRATEGIES 66
OTC PHARMACEUTICALS. 67
REGULATION.67
Marketing Registration67
Labelling67
MARKET SIZE.67
COMPETITION.67
Trade Association68
AFAMELA.68
Company Intelligence.69
Genomma Lab69
Espicom Business vi Intelligence Q1 2010
Mexico WPM
GENERIC PHARMACEUTICALS. 71
REGULATION.71
Marketing Registration71
MARKET SIZE 72
COMPETITION 72
Trade Associations.73
AMEGI.73
ANAFAM.73
DINAMEGI 74
Company Intelligence.74
Apotex 74
Kendrick. 74
Perrigo 74
Tecnofarma 74
Teva.75
Wal-Mart (Medi-Mart).75
Competitive Strategies.76
BIOLOGICS & BIOSIMILARS 77
REGULATION 77
COMPETITION 77
Company Intelligence.77
Landsteiner Scientific77
Pisa Farmacéutica78
Probiomed.78
Silanes78
CONCLUSIONS: OPPORTUNITIES & CHALLENGES. 79
Strategic Espicom Analysis.79
MACROENVIRONMENT.79
EPIDEMIOLOGY79
HEALTHCARE80
REGULATORY AFFAIRS80
PRICING & REIMBURSEMENT81
DISTRIBUTION CHANNELS81
MARKET81
COMPETITION 82
OTC PHARMACEUTICALS.82
GENERIC PHARMACEUTICALS82
BIOLOGICS & BIOSIMILARS.83
Radar Analysis. 84
SWOT Analysis. 84
DIRECTORY.85
GOVERNMENT ORGANISATIONS 85
PHARMACEUTICAL PRODUCERS 85
Foreign Private Producers85
Local Private Producers85
OTC Producers86
Generic Producers.86
Biologics & Biosimilars Producers.86
TRADE ORGANISATIONS 86
METHODOLOGY & SOURCES. 87
Espicom Business Q1 2010 Intelligence vii
WPM Mexico
List of Tables
Espicom Analysis of the Pharmaceutical Market, 2010 2
Key Data Projections, 2010-2015 3
Political Landscape, 2010 4
Regional Comparison of Projected Economies, 2015 5
Projected Economy, 2010-2015. 5
Regional Comparison of Projected Demographics, 2015 7
Projected Demographics, 2010-2015 7
Projected Population by State, 2010. 8
Summary of Demographic Indicators, 2007-2008. 9
Demographic Indicators, 2000-2007. 10
Leading Causes of Death, 2000-200811
Leading Reportable Diseases, 2007.12
Leading Communicable Diseases, 2000-200812
AIDS Cases, 1983-2008.13
IMSS & ISSSTE Insured Population, 2000-2008 (000s). 16
Regional Comparison of Projected Health Expenditure, 2015 17
Projected Health Expenditure, 2010-2015 17
Healthcare Expenditure, 2007 18
Hospitals & Beds, 2008. 19
Selected Public Hospital Resources, 2000-2006. 20
Selected Private Hospital Resources, 2000-2008 20
Médica Sur’s Revenues, 2004-2008 (Million Pesos). 21
Consulting Rooms by Sector, 2000-2008 23
Hospital Discharges by Sector, 2001-2008 (000s). 24
Hospital Surgical Procedures by Sector, 2001-2008 (000s). 24
Outpatient Consultations by Sector, 2000-2008 (000s). 25
Regional Comparison of Projected Physicians, 2015. 26
Projected Physicians, 2010-2015. 26
Physicians by Sector, 2000-2008 27
Nurses by Sector, 2000-2008 27
Legal Pharmaceutical Registration Requirements.30
Technical, Preclinical & Clinical Registration Requirements30
Time for Registration Approval & Fees30
Registration Renewal Requirements 31
Import Fees Applicable from 1st January 2007 32
Members of DIPROFAR, 2008 35
GCS’s Sales, 2004-September 2009. 36
Members of ANADIM, 2007 38
Farmacias Benavides’ Figures, 2002-September 2009. 39
Corporativo Fragua’s Figures, 2005-September 200940
Regional Comparison of Projected Pharmaceutical Markets, 2015 41
Projected Pharmaceutical Market, 2010-2015. 42
Pharmaceutical Market, 2010. 43
Private Pharmacy & Public Sectors at Retail Prices, 2009 (US$ Billion) 43
Clinical Studies, 2003-200646
Pharmaceutical Production Indicators, 1999-200646
Pharmaceutical Production Breakdown, 2005-2006 (Billion Pesos). 47
Pharmaceutical Exports by Category, 2003-2007 (US$000s).48
Leading Destinations of Pharmaceuticals, 2007 (US$000s). 49
Imports of Raw Materials by Country/Region, 2007 (US$000s). 52
Imports of Antisera & Vaccines by Country/Region, 2007 (US$000s). 53
Imports of Medicaments by Country/Region, 2007 (US$000s) 54
Espicom Business viii Intelligence Q1 2010
Mexico WPM
Balance of Pharmaceutical Trade, 2003-2007 (US$000s) 55
Members of AMIIF, 2009. 56
Members of CANIFARMA, 2009 57
AstraZeneca’s Sales, 2005-2007. 58
Novartis Sales by Division, 2007. 61
Members of AFAMELA, 200968
Genomma Lab’s Sales, 2005-June 2009. 69
Genomma Lab’s Bestselling Products by Sales, 2008. 70
NOM-177-SSA1-1998’s Generic Tests. 71
Members of AMEGI, 2009. 73
Members of ANAFAM, 2007 73
Espicom Analysis of the Pharmaceutical Market, 2010 83
SWOT Analysis of the Pharmaceutical Market, 201084
List of Charts
Regional Comparison of Projected Pharmaceutical Markets, 2015 42
Pharmaceutical Exports, 1995-2007 (US$ Millions). 47
Change in Pharmaceutical Exports, 1996-2007 (US$ Millions)48
Pharmaceutical Imports, 1995-2007 (US$ Billions) 50
Change in Pharmaceutical Imports, 1996-2007 (US$ Billions) 50
Pharmaceutical Imports by Country/Region, 2007 (%). 51
Pharmaceutical Balance of Trade, 1995-2007 (US$ Billions) 55
Radar Graph of the Pharmaceutical Market, 2010.84

For full details, please email keithw@cmsinfo.com

Top of Page

Buy now!

PDF single user

 GBP 595.00   

Paper

 GBP 595.00   

Online Access

 GBP 595.00   

Your personal guarantee

Top of Page